LU67546A1 - - Google Patents

Info

Publication number
LU67546A1
LU67546A1 LU67546A LU67546DA LU67546A1 LU 67546 A1 LU67546 A1 LU 67546A1 LU 67546 A LU67546 A LU 67546A LU 67546D A LU67546D A LU 67546DA LU 67546 A1 LU67546 A1 LU 67546A1
Authority
LU
Luxembourg
Application number
LU67546A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU67546A1 publication Critical patent/LU67546A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
LU67546A 1972-05-05 1973-05-04 LU67546A1 (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2114272A GB1430942A (en) 1972-05-05 1972-05-05 21-substituted 3alpha-hydroxy pregnanes

Publications (1)

Publication Number Publication Date
LU67546A1 true LU67546A1 (en:Method) 1973-07-13

Family

ID=10157915

Family Applications (1)

Application Number Title Priority Date Filing Date
LU67546A LU67546A1 (en:Method) 1972-05-05 1973-05-04

Country Status (16)

Country Link
JP (1) JPS4961150A (en:Method)
AT (1) AT355232B (en:Method)
AU (1) AU475168B2 (en:Method)
BE (1) BE799102A (en:Method)
CA (1) CA1013341A (en:Method)
CH (1) CH617710A5 (en:Method)
DE (1) DE2322532A1 (en:Method)
ES (1) ES414411A1 (en:Method)
FR (1) FR2183792B1 (en:Method)
GB (1) GB1430942A (en:Method)
IE (1) IE37596B1 (en:Method)
IL (1) IL42196A (en:Method)
LU (1) LU67546A1 (en:Method)
NL (1) NL7306234A (en:Method)
SE (1) SE400771B (en:Method)
ZA (1) ZA733035B (en:Method)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
ES2151593T3 (es) * 1994-02-14 2001-01-01 Euro Celtique Sa Androstanos y pregnanos para modulacion alosterica del receptor de gaba.
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
JP4915427B2 (ja) * 2009-03-30 2012-04-11 ブラザー工業株式会社 液体供給ジョイント、これを使用した液体吐出ヘッド及び記録装置
EP2766380B1 (en) 2011-10-14 2019-04-24 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
EP4295908A3 (en) 2012-01-23 2024-03-20 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
NZ705410A (en) 2012-08-21 2018-03-23 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
PT3021852T (pt) 2013-07-19 2021-04-21 Sage Therapeutics Inc Esteroides neuroativos, composições e utilizações das mesmas
CN113750107B (zh) 2013-08-23 2025-02-11 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ES2808855T3 (es) 2014-10-16 2021-03-02 Sage Therapeutics Inc Composiciones y métodos para tratar trastornos del SNC
EP4527461A3 (en) 2014-10-16 2025-06-25 Sage Therapeutics, Inc. A compound, compositions thereof and this compound for use in methods of treating cns disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
CA3158448A1 (en) 2016-03-08 2017-09-14 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
NZ790187A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C7, C12, and C16 substituted neuroactive steroids and their methods of use
NZ790226A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, C20, and C21 substituted neuroactive steroids and their methods of use
PE20230244A1 (es) 2019-05-31 2023-02-07 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1346292A (fr) * 1962-09-14 1963-12-20 Roussel Uclaf Nouveau procédé de préparation des 21-amino stéroïdes
US3144446A (en) * 1963-12-20 1964-08-11 Upjohn Co Mono and bis nu-(3alpha, 17alpha-dihydroxy-11, 20-dioxo-5beta-pregnan-21-yl) quaternary ammonium salts of triethylenediamine

Also Published As

Publication number Publication date
IE37596B1 (en) 1977-08-31
AU5528473A (en) 1974-11-07
FR2183792A1 (en:Method) 1973-12-21
CH617710A5 (en) 1980-06-13
JPS4961150A (en:Method) 1974-06-13
BE799102A (fr) 1973-11-05
DE2322532A1 (de) 1973-11-22
AU475168B2 (en) 1976-08-12
CA1013341A (en) 1977-07-05
NL7306234A (en:Method) 1973-11-07
SE400771B (sv) 1978-04-10
ATA395173A (de) 1979-07-15
IL42196A0 (en) 1973-07-30
IL42196A (en) 1978-10-31
ZA733035B (en) 1974-04-24
IE37596L (en) 1973-11-05
GB1430942A (en) 1976-04-07
ES414411A1 (es) 1976-02-01
AT355232B (de) 1980-02-25
FR2183792B1 (en:Method) 1977-07-15

Similar Documents

Publication Publication Date Title
FR2169659A5 (en:Method)
FR2183792B1 (en:Method)
JPS4973804A (en:Method)
JPS4951862A (en:Method)
JPS495745U (en:Method)
JPS5137439Y2 (en:Method)
JPS525642Y2 (en:Method)
JPS498984A (en:Method)
FR2209592A1 (en:Method)
JPS5238385Y2 (en:Method)
FR2170353A5 (en:Method)
FR2168952A1 (en:Method)
JPS48101717U (en:Method)
HU168850B (en:Method)
JPS4928809U (en:Method)
JPS4940961A (en:Method)
JPS4967333U (en:Method)
FR2206778A5 (en:Method)
JPS4926046U (en:Method)
CS155634B1 (en:Method)
CS150896B1 (en:Method)
CS152721B1 (en:Method)
JPS4877344A (en:Method)
JPS4990951U (en:Method)
CS153918B1 (en:Method)